Hospital & Healthcare Services · Founded 1989 · www.jaipurhospital.co.in · BSE 524548 · · ISIN INE465H01012
No Notes Added Yet
Business
Sharma East India Hospitals & Medical Research Ltd (SHARMA E.HOS) is an Indian company primarily engaged in the Hospital & Healthcare Services sector. Its core business involves operating multi-specialty hospitals and potentially engaging in medical research activities. The company's business model revolves around providing comprehensive healthcare services, including outpatient consultations, inpatient care, diagnostic services, emergency services, and various surgical procedures across multiple medical disciplines. It generates revenue primarily through patient fees for medical services, consultations, procedures, room charges, diagnostic tests, and potentially pharmacy sales and research grants.
Revenue Mix
While specific revenue contribution data is not publicly available here, a typical hospital's revenue mix would generally include:
Inpatient Services: (Likely the largest segment) Revenue from patient admissions, surgeries, long-term care, and intensive care units.
Outpatient Services: Consultations, day-care procedures, and minor treatments.
Diagnostic Services: Radiology (X-rays, MRI, CT scans), pathology, and other laboratory tests.
Pharmacy & Consumables: Sales of medicines and medical supplies used during treatment.
Emergency & Critical Care: Services provided in urgent medical situations.
For a hospital chain, inpatient services, especially complex surgeries and prolonged treatments, usually account for the largest portion of revenue.
Industry
The Indian hospital and healthcare services industry is vast and growing, driven by a large population, increasing disease burden, rising disposable incomes, and improving health insurance penetration. The industry is characterized by a mix of large corporate hospital chains, regional players, standalone hospitals, and government facilities. Sharma East India Hospitals & Medical Research Ltd, by its name, suggests a regional focus within Eastern India. Its positioning would likely be as a prominent regional healthcare provider, competing with both larger national hospital chains that have a presence in East India, as well as smaller, local hospitals and specialty clinics. Its success depends on its ability to offer competitive quality of care, attract skilled medical professionals, and manage operational costs effectively within its primary operating regions.
MOAT
For a hospital chain, potential competitive advantages include:
Brand Reputation & Trust: A long-standing reputation for quality medical care, ethical practices, and successful patient outcomes can build significant trust and brand loyalty.
Doctor Talent Pool: The ability to attract and retain highly skilled and renowned doctors and medical professionals is a crucial differentiator.
Location & Accessibility: Strategically located hospitals in densely populated areas with good connectivity can command higher patient volumes.
Specialized Services: Expertise in niche or complex medical specialties can attract patients from a wider geographical area.
Patient Switching Costs: For serious or ongoing medical conditions, patients often prefer to stick with a familiar hospital and medical team, creating an implicit switching cost. The company's "East India" focus suggests it might have built strong regional ties and a local reputation.
Growth Drivers
Demographic Tailwinds: India's large and growing population, coupled with an aging demographic, increases the demand for healthcare services.
Rising Disease Burden: Increasing prevalence of lifestyle diseases (diabetes, heart disease) and chronic conditions.
Increasing Healthcare Spending: Growing disposable incomes and rising health awareness lead to higher per capita healthcare expenditure.
Government Initiatives & Insurance Penetration: Schemes like Ayushman Bharat and growing private health insurance coverage expand the addressable market.
Expansion: Opening new hospitals, increasing bed capacity in existing facilities, and adding new specialties or diagnostic capabilities.
Medical Tourism: If the company develops high-quality, cost-effective specialty services, it could attract international patients.
Risks
Regulatory & Pricing Risks: Government interventions, such as price caps on medical procedures, drugs, or devices, can impact profitability. Changes in health insurance policies or reimbursement rates also pose risks.
Intense Competition: The Indian healthcare market is highly competitive, leading to potential price wars and pressure on margins.
Talent Attrition: Difficulty in attracting and retaining highly qualified doctors, nurses, and medical staff can impact service quality and operational costs.
High Capital Expenditure: Establishing and expanding hospitals requires significant capital investment, leading to potential debt accumulation and long payback periods.
Medical Malpractice & Reputational Risks: Adverse patient outcomes, medical errors, or ethical controversies can severely damage reputation and lead to legal liabilities.
Technological Obsolescence: Rapid advancements in medical technology necessitate continuous investment, posing a financial burden.
Management & Ownership
As with many Indian companies, Sharma East India Hospitals & Medical Research Ltd is likely promoter-led, meaning a founding family or group holds a significant controlling stake. The quality of management would depend on their experience in hospital administration, strategic vision, ability to navigate regulatory complexities, and track record in delivering patient care and financial performance. Without specific details on the management team or ownership breakdown, a definitive assessment cannot be made, but typically, promoter-backed companies in India often exhibit strong long-term commitment.
Outlook
The outlook for Sharma East India Hospitals & Medical Research Ltd is influenced by strong underlying demand for healthcare services in India, driven by favorable demographics and increasing affordability. The company could benefit from the ongoing formalization and consolidation of the Indian healthcare sector, potentially leveraging its regional presence.
The bull case would see the company successfully expanding its footprint, enhancing its brand reputation through quality care and specialized services, and effectively navigating the evolving regulatory landscape. Growth could be fueled by increased patient volumes, higher utilization rates of existing facilities, and a robust strategy to attract and retain medical talent.
Conversely, the bear case highlights risks from aggressive competition, potential pricing pressures from regulators, high capital expenditure requirements leading to financial strain, and the ongoing challenge of medical professional retention. An inability to adapt to technological advancements or manage operational efficiencies could also hinder growth and profitability. The company's ability to maintain its competitive edge and financial health within a dynamic and often price-sensitive market will be key to its long-term success.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 2 | 7 | 9 | 8 | 6 | 9 | 9 | 10 | 7 | 11 |
| Other Income | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 7 | 7 | 9 | 8 | 6 | 10 | 9 | 10 | 7 | 11 |
| Total Expenditure | 6 | 6 | 8 | 7 | 5 | 9 | 8 | 9 | 6 | 10 |
| Operating Profit | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Provision for Tax | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjustments | 0 | 0 | -0 | 0 | -0 | 0 | -0 | 0 | 0 | -0 |
| Profit After Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted Earnings Per Share | 0.1 | 0.8 | 1 | 0.9 | 1.1 | 1 | 1 | 0.5 | 1.3 | 0.8 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 16 | 17 | 17 | 16 | 15 | 16 | 8 | 17 | 21 | 19 | 30 | 37 |
| Other Income | 1 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 5 | 0 | 0 |
| Total Income | 17 | 17 | 17 | 16 | 16 | 16 | 11 | 17 | 21 | 24 | 30 | 37 |
| Total Expenditure | 15 | 16 | 16 | 15 | 14 | 14 | 9 | 15 | 17 | 20 | 26 | 33 |
| Operating Profit | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 4 |
| Interest | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Provision for Tax | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Profit After Tax | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Adjusted Earnings Per Share | 1.7 | 0.1 | 0.3 | 0.4 | 0.8 | 0.9 | 1.9 | 2.1 | 2.5 | 2 | 3.8 | 3.6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 58% | 21% | 13% | 6% |
| Operating Profit CAGR | 33% | 26% | 15% | 7% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -41% | NA% | NA% | NA% |
| ROE Average | 12% | 9% | 9% | 6% |
| ROCE Average | 14% | 12% | 12% | 9% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 6 | 6 | 7 | 8 | 8 | 8 | 9 | 10 | 11 | 11 | 12 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 6 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 2 | 7 | 8 | 7 | 13 | 9 | 8 | 8 | 11 | 12 | 14 |
| Total Liabilities | 15 | 15 | 18 | 16 | 22 | 20 | 19 | 19 | 24 | 25 | 28 |
| Fixed Assets | 7 | 6 | 6 | 6 | 5 | 4 | 6 | 7 | 9 | 8 | 9 |
| Other Non-Current Assets | 1 | 0 | 2 | 2 | 2 | 4 | 2 | 2 | 3 | 10 | 4 |
| Total Current Assets | 7 | 9 | 9 | 8 | 15 | 12 | 11 | 10 | 12 | 7 | 14 |
| Total Assets | 15 | 15 | 18 | 16 | 22 | 20 | 19 | 19 | 24 | 25 | 28 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 0 | 0 | 0 | 0 | 5 | 0 | 2 | 0 | 1 | 1 |
| Cash Flow from Operating Activities | -0 | -0 | 1 | 3 | -1 | 1 | 1 | 2 | 1 | -1 | 7 |
| Cash Flow from Investing Activities | -0 | -0 | -1 | -0 | 2 | -1 | 3 | -2 | -4 | 5 | -3 |
| Cash Flow from Financing Activities | -1 | 0 | -0 | -3 | 5 | -5 | -2 | -2 | 3 | -4 | -3 |
| Net Cash Inflow / Outflow | -1 | 0 | -0 | 0 | 5 | -5 | 2 | -2 | 0 | -0 | -0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 5 | 0 | 2 | 0 | 1 | 1 | 0 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 1.74 | 0.09 | 0.26 | 0.4 | 0.81 | 0.93 | 1.94 | 2.07 | 2.54 | 2.02 | 3.79 |
| CEPS(Rs) | 3.58 | 1.88 | 2.38 | 2.29 | 2.4 | 2.24 | 3.91 | 4.45 | 6.77 | 6.53 | 9.38 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 15.62 | 15.65 | 20.12 | 20.53 | 21.37 | 22.5 | 24.45 | 26.56 | 29.53 | 31.54 | 34.36 |
| Core EBITDA Margin(%) | 7.59 | 5.13 | 9.52 | 9.14 | 4.33 | 11.92 | -8.08 | 13.24 | 15.92 | -10.13 | 12.22 |
| EBIT Margin(%) | 7.28 | 2.99 | 6.97 | 5.7 | 8.31 | 9.47 | 18.82 | 9.01 | 9.52 | 10.53 | 7.13 |
| Pre Tax Margin(%) | 2.65 | 0.2 | 0.65 | 1.13 | 2.33 | 2.33 | 10.29 | 4.88 | 3.83 | 5.42 | 4.73 |
| PAT Margin (%) | 3.49 | 0.17 | 0.49 | 0.82 | 1.81 | 1.89 | 7.84 | 3.99 | 4.02 | 3.58 | 4.17 |
| Cash Profit Margin (%) | 7.18 | 3.58 | 4.55 | 4.69 | 5.34 | 4.54 | 15.77 | 8.57 | 10.73 | 11.57 | 10.31 |
| ROA(%) | 3.69 | 0.2 | 0.51 | 0.78 | 1.38 | 1.46 | 3.29 | 3.59 | 3.9 | 2.71 | 4.71 |
| ROE(%) | 10.55 | 0.58 | 1.43 | 1.98 | 3.87 | 4.25 | 8.27 | 8.12 | 9.06 | 6.61 | 11.5 |
| ROCE(%) | 9.01 | 4.21 | 8.7 | 6.52 | 7.7 | 8.88 | 10.01 | 10.64 | 12.03 | 11.1 | 13.87 |
| Receivable days | 35.8 | 51.05 | 53.69 | 63.51 | 83.02 | 92.56 | 166.74 | 65 | 67.58 | 67.69 | 55.77 |
| Inventory Days | 2.71 | 8.22 | 13.48 | 14.37 | 15.63 | 13.94 | 26.46 | 10.94 | 8.61 | 11.84 | 23.53 |
| Payable days | 119.4 | 120.44 | 0 | 0 | 3538.84 | 238.8 | 525.58 | 257.23 | 296.74 | 318.01 | 213.48 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.65 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.17 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.56 | 0.56 | 0.62 | 0.53 | 0.61 | 0.65 | 0.87 | 0.43 | 0.53 | 0.42 | 0.88 |
| EV/Core EBITDA(x) | 5.09 | 8.71 | 5.64 | 5.54 | 5.17 | 5.4 | 3.25 | 3.18 | 3.24 | 2.28 | 6.62 |
| Net Sales Growth(%) | 30.87 | 5.18 | -0.4 | -6.65 | -7.95 | 9.76 | -49.71 | 109.56 | 21.64 | -10.63 | 61.27 |
| EBIT Growth(%) | -26.99 | -56.72 | 131.89 | -23.6 | 34.05 | 25.12 | -0.04 | 0.27 | 28.65 | -1.19 | 9.14 |
| PAT Growth(%) | -20.34 | -94.75 | 180.92 | 56.84 | 101.59 | 15.06 | 108.27 | 6.74 | 22.62 | -20.5 | 87.68 |
| EPS Growth(%) | -20.34 | -94.75 | 180.81 | 56.85 | 101.57 | 15.07 | 108.27 | 6.74 | 22.62 | -20.5 | 87.68 |
| Debt/Equity(x) | 0.99 | 1.08 | 1 | 0.71 | 1.38 | 0.9 | 0.67 | 0.45 | 0.79 | 0.45 | 0.19 |
| Current Ratio(x) | 3.01 | 1.19 | 1.14 | 1.14 | 1.16 | 1.23 | 1.41 | 1.25 | 1.05 | 0.57 | 1.05 |
| Quick Ratio(x) | 2.95 | 1.11 | 1.06 | 1.05 | 1.12 | 1.17 | 1.34 | 1.19 | 1 | 0.52 | 0.82 |
| Interest Cover(x) | 1.57 | 1.07 | 1.1 | 1.25 | 1.39 | 1.33 | 2.21 | 2.19 | 1.67 | 2.06 | 2.97 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.09 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +58% | +21% | +13% | +6% |
| Operating Profit CAGR | +33% | +26% | +15% | +7% |
| PAT CAGR | 0% | 0% | — | 0% |
| Share Price CAGR | -41% | — | — | — |
| ROE Average | +12% | +9% | +9% | +6% |
| ROCE Average | +14% | +12% | +12% | +9% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 | 53.63 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 | 46.37 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.